ArticleBJU international2022

The BARCODE1 Pilot: a feasibility study of using germline single nucleotide polymorphisms to target prostate cancer screening.

Sarah Benafif et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.